Oxford BioDynamics (LON:OBD) Issues Quarterly Earnings Results

Oxford BioDynamics (LON:OBD) posted its quarterly earnings results on Tuesday. The biotechnology company reported GBX (0.10) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford BioDynamics had a negative return on equity of 451.74% and a negative net margin of 825.61%.

Oxford BioDynamics Stock Performance

Shares of LON:OBD traded up GBX 0.02 on Friday, hitting GBX 0.11. 18,351,965 shares of the company were exchanged, compared to its average volume of 16,501,012. Oxford BioDynamics has a 1-year low of GBX 0.08 and a 1-year high of GBX 0.78. The stock’s 50 day moving average price is GBX 0.18 and its 200 day moving average price is GBX 0.22. The company has a current ratio of 2.01, a quick ratio of 2.80 and a debt-to-equity ratio of 131.61. The firm has a market capitalization of £4.55 million, a P/E ratio of -0.13 and a beta of 0.42.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.